# VS-7375

Source: https://onco.cc/drugs/vs-7375/  
OnCo record `vs-7375` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VS-7375 is an experimental small-molecule drug from Verastem in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.

## Summary

VS-7375 is a small-molecule drug developed by Verastem. Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: An oral KRAS G12D (ON/OFF) inhibitor. ClinicalTrials.gov describes the intervention as: VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer. The largest, NCT07020221, plans to enrol 295 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: An oral KRAS G12D (ON/OFF) inhibitor.

## Sources

- ClinicalTrials.gov: trials of VS-7375: https://clinicaltrials.gov/search?intr=VS-7375

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)
- trials: [A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors](https://onco.cc/trials/nct07020221/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer](https://onco.cc/trials/nct07659795/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07659782/), [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer](https://onco.cc/trials/nct07644559/)

---
JSON: https://onco.cc/api/v1/entities/vs-7375.json